《Clinical trial of PB103 allogeneic immune cell therapy》

The treatment course of PB103 with allogeneic cells has passed TFDA IND verification and is approved for clinical phase I/IIa execution (August 109)

clinical Ι/ Phase IIa open trial, evaluation of safety and efficacy of standard treatment combined with allogeneic PB103 immune cell preparation in patients with malignant or recurrent solid cancer

Host of the Hematology and Oncology Department Program at the Third Military General Hospital: Dr. Dai Mingjie